Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC

Transformative acquisition significantly expands Salarius oncology pipeline into the targeted degradation space with ability to go after undruggable cancer-promoting targets, a rapidly growing area of cancer drug development with multi-billion-dollar market potential.